| Title |
SENTI-101, a preparation of mesenchymal stromal cells engineered to express IL-12 and IL-21, induces localized and durable anti-tumor immunity in preclinical models of peritoneal solid tumors
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, July 2021
|
| DOI | 10.1158/1535-7163.mct-21-0030 |
| Pubmed ID | |
| Authors |
Alba Gonzalez-Junca, Frances D Liu, Archana S Nagaraja, Alyssa Mullenix, Chen-Ting Lee, Russell M Gordley, Daniel O Frimannsson, Ori Maller, Brian S Garrison, Dharini Iyer, Anissa Benabbas, Tiffany A Truong, Allison Quach, Mengxi Tian, Rowena Martinez, Rishi Savur, Alyssa Perry-McNamara, Denny Nguyen, Niran Almudhfar, Carmina Blanco, Christina Huynh, Asish Nand, Yu-An E Lay, Ashita Magal, Sravani Mangalampalli, Philip J Lee, Timothy K Lu, Gary Lee |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 55% |
| France | 1 | 9% |
| Hong Kong | 1 | 9% |
| Unknown | 3 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 82% |
| Practitioners (doctors, other healthcare professionals) | 1 | 9% |
| Science communicators (journalists, bloggers, editors) | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 48% |
| Student > Ph. D. Student | 3 | 14% |
| Student > Master | 2 | 10% |
| Unspecified | 1 | 5% |
| Student > Bachelor | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 3 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Immunology and Microbiology | 7 | 33% |
| Biochemistry, Genetics and Molecular Biology | 5 | 24% |
| Agricultural and Biological Sciences | 2 | 10% |
| Unspecified | 1 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 4 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2022.
All research outputs
#5,645,663
of 23,523,017 outputs
Outputs from Molecular Cancer Therapeutics
#1,291
of 3,916 outputs
Outputs of similar age
#115,457
of 443,556 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#10
of 59 outputs
Altmetric has tracked 23,523,017 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,916 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 443,556 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.